This platform provides no-code configuration for regulated disease management tools across any therapeutic area, a library of pre-built modules, device connectivity, a Cloud-agnostic framework for flexible hosting, accessible APIs and integration capabilities, support for diagnostic and predictive AI algorithms, a marketplace, and more to advance digital-first care and research.

The Series D funding round, combined with investments from industry partners since its Series C round, has led to the issuance of over $80 million in shares by Huma. With this round, Huma has raised over $300 million in total. The Series D attracted new and existing strategic and financial investors, including AstraZeneca, HAT Technology Fund 4 by HAT SGR, HV Fund by Hitachi Ventures, Leaps by Bayer, among others. HSBC Bank plc acted as an advisor to Huma during the fundraising process.

Alongside the Series D funding, Huma is also introducing the Huma Cloud Platform – a technology ecosystem designed not only to support its digital health initiatives but also to enable others to launch and scale their projects efficiently. Built on a strong regulatory foundation, the Huma Cloud Platform aims to reduce the development and launch time for digital health projects from years to just a few days.

In 2023, Huma achieved a significant milestone by becoming the first and only configurable, disease-agnostic FDA Class II, EuMDR Class IIb, and Saudi FDA Class C platform, enabling rapid, code-free configuration with the ability to host AI/ML models. This regulatory status greatly lowers the cost, time, and risks associated with bringing digital health projects to fruition via the Huma Cloud Platform.

Dr Juergen Eckhardt, EVP, Head of Leaps by Bayer and Pharmaceuticals Business, Development & Licensing commented: “We have known Huma for several years and we've been impressed by their remarkable progress. We have seen this first-hand. They have demonstrated strong growth and excellent metrics. With their next-generation AI capabilities and Huma Cloud platform, Huma can partner with pharma companies to deliver efficient digital health solutions to patients focused on predictive and proactive care.

“Pharmaceutical companies need financially and technically efficient digital solutions to minimise spending on efforts that are duplicative or can't scale. The Huma Cloud Platform enables companies to streamline how they bring digital medicine, companion apps, and data collection capabilities to patients from the R&D phase to post-launch.”

Huma is now offering this platform to customers, complete with a Software Development Kit (SDK) to accelerate the development of similar applications or embed functionalities into existing solutions. To date, Huma’s technology has been implemented in over 3,000 hospitals and clinics, engaging and screening over 35 million individuals, with 1.8 million active users across 70+ countries. Huma’s US business has expanded significantly with new reimbursement codes. The RPM product, built on the Huma Cloud Platform for respiratory use cases, now covers 140,000 contracted lives. As a result, the company has doubled its revenue year-on-year and aims to become profitable this year.

Huma collaborates with more than half of the top 20 pharmaceutical companies globally and has played a key role in major national healthcare projects worldwide.

In partnership with Google and other entities, Huma is developing new AI models that will enable its Cloud Platform users to care for many more patients with less effort. For instance, the ‘10x Nurse’ feature significantly reduces administrative tasks and automates the patient review process, keeping humans involved for oversight. This opens new possibilities, such as efficiently managing chronic diseases with fewer staff or using real-time monitoring systems to ensure patients are on the correct treatment pathways.

Looking forward, the integration of the Huma Cloud Platform with next-generation AI models will allow Huma to make a more substantial impact through its digital-first care and research initiatives. It will also support startups and enterprises in launching the digital solutions they need faster and more cost-effectively, enabling them to focus on project success rather than the challenges of scaling technology or navigating regulatory hurdles.

Dan Vahdat, Founder and CEO of Huma, said: “I am thankful for the support of our new and existing shareholders, helping our vision become a reality, which we are closer to than ever before. We are here to accelerate the adoption of digital and AI across care and research, and we do that by making the building of digital health solutions for care and research easy. We like to think of Huma Cloud Platform much like Shopify but for digital health instead of e-commerce. We believe when digital and AI are scaled, they become affordable for both the poor and the rich. They remain consistent and will help us transition medicine from being reactive to proactive.”